Pixium Vision Reports Retinal Implant Business Success

BusinessWire: Pixium Vision says it is the only company in the world to develop in parallel two distinct retinal bionic implant platforms. IRIS II, the company’s first system, targeting retinitis pigmentosa, and PRIMA, the second generation miniaturized wireless implant, better suited for Age Related Macular Degeneration (AMD) will allow the company to address an estimated market of more than 4 million patients in Europe and North America.

Over the last quarter of 2015, the company made significant progress on IRIS II, its epi-retinal bionic system equipped with an asynchronous bioinspired image sensor. IRIS II is said to be the first epi-retinal device to be equipped with 150 electrodes worldwide. In December 2015, the company received the approval from the French regulatory authority ANSM to initiate clinical study for patients who have lost sight due to retinitis pigmentosa. The company has also received the Austrian approval. Further national approvals are expected in the coming months.

In early 2016, the company announced positive preclinical safety and feasibility data for PRIMA, its second generation bionic system. Stanford University, demonstrated thermal safety of near infrared stimulation of PRIMA in a well-established animal model for retinal damage assessment in laser treatment.

A Vimeo video explains the company's technology"

Pixium IRIS implant

Pixium PRIMA implant